SH-SY5Y

SH-SY5Y
Name	SH-SY5Y
Species	Human (Homo sapiens)
Tissue	Neuroblastoma
Morphology	Neuroblastic
Availability	Cell banks, repositories

SH-SY5Y SH-SY5Y is a human neuroblastoma-derived cell line extensively used in neuroscience research, derived from metastatic tumor material and adapted for in vitro studies. It serves as a model for neuronal differentiation, dopaminergic phenotype examination, and neurodegenerative disease modeling in laboratories affiliated with institutions such as National Institutes of Health, Max Planck Society, University of Cambridge, Harvard University, and Stanford University.

History and origin

The lineage traces to clonal derivatives established in the 1970s from a neuroblastoma biopsy originally associated with clinical reports from oncology centers like Memorial Sloan Kettering Cancer Center and laboratories influenced by researchers at Cold Spring Harbor Laboratory, Karolinska Institute, and University of California, San Francisco. Subsequent subcloning and characterization were influenced by work from cell line repositories including American Type Culture Collection and investigative teams at Scripps Research and Institut Pasteur. Historical studies intersect with archival tumor banking efforts from hospitals such as Mayo Clinic and Johns Hopkins Hospital.

Cell line characteristics

The cells display a neuroblastic morphology reminiscent of models used by neurobiology groups at Max Planck Institute for Brain Research, Columbia University, and University College London. Characteristic features include catecholaminergic enzyme expression and neuronal markers also studied in contexts at Weizmann Institute of Science and Riken. Karyotypic abnormalities were described alongside cytogenetic reports from centers like European Molecular Biology Laboratory and Fred Hutchinson Cancer Center.

Culture and differentiation protocols

Standard propagation methods are practiced in facilities associated with University of Oxford, Yale University, and University of Toronto, typically employing media formulations used in protocols by researchers at Massachusetts Institute of Technology, ETH Zurich, and University of Melbourne. Differentiation regimens exploiting agents such as retinoic acid and brain-derived factors reflect approaches developed at laboratories in University of Pennsylvania, Karolinska Institute, and Peking University. Techniques often mirror procedural standards from National Cancer Institute, University of Washington, and Seoul National University.

Genetic and molecular profile

Genomic characterizations align with sequencing efforts performed by consortia including 1000 Genomes Project, The Cancer Genome Atlas, and institutions like Wellcome Sanger Institute and Broad Institute. Transcriptomic and proteomic signatures have been compared to datasets curated by European Bioinformatics Institute and National Center for Biotechnology Information. Reports discuss expression of genes and pathways interrogated in projects at Cold Spring Harbor Laboratory, Howard Hughes Medical Institute, and Max Planck Institute for Molecular Genetics.

Applications in neuroscience and disease modeling

Researchers at University of California, Los Angeles, Imperial College London, and Johns Hopkins University employ the line to model Parkinsonian neurodegeneration, Alzheimer's-related pathology, and amyotrophic lateral sclerosis mechanisms. Studies intersect with clinical research programs at National Institute of Neurological Disorders and Stroke, Mount Sinai Health System, and Mayo Clinic and reflect translational efforts seen in collaborations with GlaxoSmithKline, Pfizer, and Novartis.

Pharmacology and toxicology studies

Pharmacological screening protocols used in pharmaceutical labs at AstraZeneca, Roche, and academic pharmacology departments such as University of Chicago and Duke University exploit the line to assess neurotoxicity, synaptic drug responses, and mitochondrial toxicants. Toxicology assessments reference regulatory guidelines promulgated by agencies like Food and Drug Administration and European Medicines Agency with preclinical testing often coordinated with contract research organizations echoing practices from Charles River Laboratories.

Limitations and criticisms

Critiques from researchers at Stanford University School of Medicine, University of Cambridge Department of Clinical Neurosciences, and University of Edinburgh highlight differences from primary human neurons and iPSC-derived models advanced at Broad Institute and Gladstone Institutes. Concerns raised in methodological reviews published by groups at Nature Publishing Group, Science Media Group, and Cell Press address karyotypic drift, tumor-derived phenotype, and reproducibility issues noted by consortia including Reproducibility Project contributors.

Resources and availability

Cell stocks and authentication services are distributed through repositories such as American Type Culture Collection, European Collection of Authenticated Cell Cultures, and institutional biobanks at Horizon Discovery Group and Coriell Institute for Medical Research. Protocols, material transfer agreements, and genomic datasets are accessible via platforms maintained by Addgene, BioRxiv, and data portals operated by National Center for Biotechnology Information and European Nucleotide Archive.

Category:Human cell lines